InsiderTrades.com logo

SONN Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 8.48%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Sonnet BioTherapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Sonnet BioTherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Sonnet BioTherapeutics Share Price & Price History

Current Price: $1.02
Price Change: ▼ Price Decrease of -2.085 (-67.26%)
As of 12/2/2025 08:59 PM ET

This chart shows the closing price history over time for SONN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Sonnet BioTherapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/14/2023Susan DexterInsiderBuy56$123.20$6,899.20191View SEC Filing Icon  
5/30/2023Albert D DyrnessDirectorBuy132$82.72$10,919.04164View SEC Filing Icon  
5/17/2023Nailesh BhattDirectorBuy142$40.48$5,748.16174View SEC Filing Icon  
5/15/2023Pankaj MohanCEOBuy2,111$38.72$81,737.923,143View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Sonnet BioTherapeutics (NASDAQ:SONN)

9.45% of Sonnet BioTherapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SONN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Sonnet BioTherapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
1/16/2026Formidable Asset Management LLC37,185$47K0.0%N/A0.525%Search for SEC Filing on Google Icon
11/18/2025Heights Capital Management Inc.3,000,000$13.74M3.8%N/A42.385%Search for SEC Filing on Google Icon
11/17/2025Pantera Capital Partners LP20,427,696$93.56M9.6%N/A288.608%Search for SEC Filing on Google Icon
11/17/2025Citadel Advisors LLC46,082$0.21M0.0%N/A0.651%Search for SEC Filing on Google Icon
11/17/2025Bank of America Corp DE16,784$77K0.0%+57,775.9%0.237%Search for SEC Filing on Google Icon
11/17/2025Boothbay Fund Management LLC56,339$0.26M0.0%N/A0.796%Search for SEC Filing on Google Icon
11/14/2025Virtu Financial LLC26,266$0.12M0.0%N/A0.371%Search for SEC Filing on Google Icon
11/14/2025Two Sigma Investments LP14,972$69K0.0%N/A0.212%Search for SEC Filing on Google Icon
11/10/2025BIT Capital GmbH48,358$0.22M0.0%N/A0.683%Search for SEC Filing on Google Icon
11/7/2025JPMorgan Chase & Co.7,537$35K0.0%N/A0.106%Search for SEC Filing on Google Icon
10/31/2025Investment House LLC10,625$49K0.0%N/A0.150%Search for SEC Filing on Google Icon
5/12/2025MMCAP International Inc. SPC133,590$0.18M0.0%N/A4.357%Search for SEC Filing on Google Icon
2/17/2025Two Sigma Investments LP19,203$28K0.0%N/A0.630%Search for SEC Filing on Google Icon
2/11/2025Virtu Financial LLC39,647$58K0.0%N/A1.300%Search for SEC Filing on Google Icon
8/15/2024Armistice Capital LLC272,000$0.26M0.0%N/A8.740%Search for SEC Filing on Google Icon
7/27/2023Virtu Financial LLC86,624$42K0.0%N/A0.315%Search for SEC Filing on Google Icon
5/19/2023Anson Funds Management LP1,760,000$0.63M0.1%N/A6.405%Search for SEC Filing on Google Icon
11/7/2022Virtu Financial LLC26,914$40K0.0%N/A0.622%Search for SEC Filing on Google Icon
8/2/2022Advisory Services Network LLC130,525$37K0.0%+158.3%0.215%Search for SEC Filing on Google Icon
5/10/2022Campion Asset Management90,612$34K0.0%N/A0.150%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Sonnet BioTherapeutics logo
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.
Read More on Sonnet BioTherapeutics

Today's Range

Now: $1.02
Low: $1.26
High: $3.23

50 Day Range

MA: $2.37
Low: $1.02
High: $5.92

52 Week Range

Now: $1.02
Low: $1.08
High: $19.30

Volume

10,084,314 shs

Average Volume

771,503 shs

Market Capitalization

$7.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48

Who are the company insiders with the largest holdings of Sonnet BioTherapeutics?

Sonnet BioTherapeutics' top insider investors include:
  1. Pankaj Mohan (CEO)
  2. Susan Dexter (Insider)
  3. Nailesh Bhatt (Director)
  4. Albert D Dyrness (Director)
  5. Richard T Kenney (Insider)
Learn More about top insider investors at Sonnet BioTherapeutics.

Sonnet BioTherapeutics Active Insiders

Pankaj Mohan
Pankaj Mohan (Age 61)
CEO
Richard T. Kenney
Richard T. Kenney (Age 68)
Insider